Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. UnicoCell Biomed Co's Revenue for the
three
months ended in Mar. 2026 was NT$6.28 Mil. UnicoCell Biomed Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$2.71 Mil.
Hence, UnicoCell Biomed Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.32.
UnicoCell Biomed Co (TPE:6794) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
UnicoCell Biomed Co Receivables Turnover Related Terms
UnicoCell Biomed Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UnicoCell Biomed Co (TPE:6794) has a Receivables Turnover of 2.32 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on UnicoCell Biomed Co and its competitors. According to the industry distribution chart, UnicoCell Biomed Co ranks #109 out of 841 companies in the Biotechnology industry, placing it in the top 13%.
Is UnicoCell Biomed Co's Receivables Turnover too high?
UnicoCell Biomed Co's current Receivables Turnover is 2.32. The Biotechnology industry median Receivables Turnover is 5.27. UnicoCell Biomed Co's value of 2.32 is 56% below this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #109 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #109 out of 841 companies for Receivables Turnover. This places UnicoCell Biomed Co in the top 13% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. UnicoCell Biomed Co's value of 2.32 is 56% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current Receivables Turnover of 2.32 is 56% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Receivables Turnover is 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Fairly Valued. The stock's GF Value™ is NT$80.95, compared to a current price of NT$75.80 — trading 6.4% below its estimated fair value. The current Receivables Turnover is 2.32 and 56% below the Biotechnology industry median of 5.27. UnicoCell Biomed Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Receivables Turnover is 2.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$75.80 is trading 6.4% below its estimated GF Value™ of NT$80.95.
GuruFocus considers UnicoCell Biomed Co to be Fairly Valued.
Key valuation signals for TPE:6794:
Receivables Turnover: 2.32
GF Value™: NT$80.95 vs. price of NT$75.80 (6.4% below fair value)
Industry Position: 56% below the Biotechnology median (#109 of 841)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
81GF Score
Get the complete analysis for TPE:6794
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
